Advertisement

Ads Placeholder
Loading...

Verastem, Inc.

2VSA.FXETRA
Healthcare
Biotechnology
4.86
0.12(2.53%)
German Market is Open • 15:00

Verastem, Inc. Fundamental Analysis

Verastem, Inc. (2VSA.F) shows weak financial fundamentals with a PE ratio of -2.23, profit margin of -6.78%, and ROE of -18.50%. The company generates $0.0B in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

Cash Position50.58%
PEG Ratio-0.97
Current Ratio3.09

Areas of Concern

ROE-18.50%
Operating Margin-5.50%
We analyze 2VSA.F's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -2345.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-2345.6/100

We analyze 2VSA.F's fundamental strength across five key dimensions:

Efficiency Score

Weak

2VSA.F struggles to generate sufficient returns from assets.

ROA > 10%
-84.99%

Valuation Score

Excellent

2VSA.F trades at attractive valuation levels.

PE < 25
-2.23
PEG Ratio < 2
-0.97

Growth Score

Weak

2VSA.F faces weak or negative growth trends.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
7.58%

Financial Health Score

Moderate

2VSA.F shows balanced financial health with some risks.

Debt/Equity < 1
1.52
Current Ratio > 1
3.09

Profitability Score

Weak

2VSA.F struggles to sustain strong margins.

ROE > 15%
-1849.74%
Net Margin ≥ 15%
-6.78%
Positive Free Cash Flow
No

Key Financial Metrics

Is 2VSA.F Expensive or Cheap?

P/E Ratio

2VSA.F trades at -2.23 times earnings. This suggests potential undervaluation.

-2.23

PEG Ratio

When adjusting for growth, 2VSA.F's PEG of -0.97 indicates potential undervaluation.

-0.97

Price to Book

The market values Verastem, Inc. at 8.17 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

8.17

EV/EBITDA

Enterprise value stands at -2.33 times EBITDA. This is generally considered low.

-2.33

How Well Does 2VSA.F Make Money?

Net Profit Margin

For every $100 in sales, Verastem, Inc. keeps $-6.78 as profit after all expenses.

-6.78%

Operating Margin

Core operations generate -5.50 in profit for every $100 in revenue, before interest and taxes.

-5.50%

ROE

Management delivers $-18.50 in profit for every $100 of shareholder equity.

-18.50%

ROA

Verastem, Inc. generates $-84.99 in profit for every $100 in assets, demonstrating efficient asset deployment.

-84.99%

Following the Money - Real Cash Generation

Operating Cash Flow

Verastem, Inc. generates limited operating cash flow of $-114.29M, signaling weaker underlying cash strength.

$-114.29M

Free Cash Flow

Verastem, Inc. generates weak or negative free cash flow of $-114.29M, restricting financial flexibility.

$-114.29M

FCF Per Share

Each share generates $-1.65 in free cash annually.

$-1.65

FCF Yield

2VSA.F converts -35.38% of its market value into free cash.

-35.38%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.23

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.97

vs 25 benchmark

P/B Ratio

Price to book value ratio

8.17

vs 25 benchmark

P/S Ratio

Price to sales ratio

12.57

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

1.52

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.09

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-18.50

vs 25 benchmark

ROA

Return on assets percentage

-0.85

vs 25 benchmark

ROCE

Return on capital employed

-0.98

vs 25 benchmark

How 2VSA.F Stacks Against Its Sector Peers

Metric2VSA.F ValueSector AveragePerformance
P/E Ratio-2.2328.54 Better (Cheaper)
ROE-1849.74%738.00% Weak
Net Margin-677.57%-43982.00% (disorted) Weak
Debt/Equity1.520.34 Weak (High Leverage)
Current Ratio3.092806.01 Strong Liquidity
ROA-84.99%-14624.00% (disorted) Weak

2VSA.F outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Verastem, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-90.03%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

84.76%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

86.84%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ